Tagitanlimab

Phase 2Monoclonal antibody

WWest China Hospital

Tagitanlimab is one of 124 small molecule programs targeting Recurrent or Metastatic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent or MetastaticNot yet recruiting

Breast CancerNot yet recruiting

Prostate CancerRecruiting

Head and Neck Squamous Cell CarcinomaNot yet recruiting

Recurrent or MetastaticPhase 2

Not yet recruiting

Breast CancerPhase 2

Not yet recruiting

Prostate CancerPhase 2

Recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tagitanlimab

WWest China Hospital

Phase 2

1 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Prostate Cancer

NCT07179783

Q4 2029

Phase 2Not yet recruiting

Recurrent or Metastatic

NCT07738757

Q4 2030

Phase 2Not yet recruiting

Breast Cancer

NCT07109284

Q1 2031

Phase 2Not yet recruiting

Head and Neck Squamous Cell Carcinoma

NCT07492914

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma

Not yet recruiting·WWest China Hospital·Phase 2·NCT07492914·30 enrolled

Breast Cancer1 trial

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

Not yet recruiting·WWest China Hospital·Phase 2·NCT07109284·55 enrolled

Prostate Cancer1 trial

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07179783·28 enrolled

Recurrent or Metastatic1 trial

A Phase II Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination With Tagitanlimab (KL-A167) as Second-Line or Later Therapy for MSI-H/dMMR Advanced Gynecological Malignancies: An Open-Label, Single-Arm, Multicenter Exploratory Trial

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07738757·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tagitanlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tagitanlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tagitanlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: WWest China Hospital

Tagitanlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Q4 2030

Q1 2031

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

Breast Cancer1 trial

Prostate Cancer1 trial

Recurrent or Metastatic1 trial

References

Drug Info

Quick Facts

Related News